Monopar Therapeutics 4

Kim R. Tsuchimoto sold 4,090 shares of Monopar Therapeutics common stock in multiple open-market transactions on August 26, 2026 under a Rule 10b5-1 plan.

On August 26, 2026, reporting person Kim R. Tsuchimoto executed a series of open-market sales of Monopar Therapeutics (MNPR) common stock under a pre-arranged Rule 10b5-1 trading plan. Across six tranches, Tsuchimoto sold an aggregate 4,090 shares at weighted average prices ranging from approximately $108.83 to $113.84 per share, for estimated total proceeds of about $457,000. Each line item represents a weighted average price derived from multiple executions within specified price ranges, and following these dispositions, Tsuchimoto’s directly held position in Monopar common stock decreased from 11,001 shares to 7,396 shares.

Filing Facts

CIK

1645469

Ticker

MNPR

Form

4

Source Type

fda

Accession

0001437749-26-029116

Alert Tier

6